Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : MP0533 is a T-cell engager, leveraging the cell surface protein CD3 as a powerful immune activator, complemented by novel control mechanisms designed to help direct CD3-mediated cytotoxicity with heightened precision. It is being studied for AML.
Brand Name : MP0533
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 16, 2023
Molecular Partners to Regain Global Rights for MP0310 from Amgen
Details : MP0310 is a dual-targeted compound, targeting both FAP and 4-1BB, that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming to avoid systemic side effects associated with 4-1BB activation.
Brand Name : MP0310
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 26, 2022
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MP0420 (ensovibep) is a COVID-19 antiviral therapeutic candidate designed specifically to inactivate SARS-CoV-2 – the virus that causes COVID-19 – with extremely high potency that is preserved against novel variants.
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 23, 2022
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Recipient : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of MP0420/SKO136 (ensovibep), a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load r...
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 10, 2022
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Recipient : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Laboratory studies using full Omicron pseudovirus confirm MP0420 (ensovibep), maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency across numerous anti-SARS-CoV-2 antibody drugs.
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 12, 2021
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In vitro data to-date demonstrate that ensovibep retains potency in inhibiting all known SARS-CoV-2 variants of concern, including the Delta variants. Ensovibep is the lead therapeutic candidate in Molecular Partners’ infectious disease pipeline.
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 16, 2021
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the results presented, neutralization assays demonstrate ensovibep’s ability to potently neutralize SARS-CoV-2 when testing the Wuhan or a reference strain.
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 20, 2021
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : DARPin-conjugated Radioligand Therapies
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $580.0 million
Deal Type : Acquisition
Details : The collaboration will combine Molecular Partners’ industry-leading ability to rapidly generate high-affinity DARPins and the RLT capabilities and expertise of Novartis. DARPins have great potential to enable robust, tumor-specific delivery of radiolig...
Brand Name : DARPin-RLTs
Molecule Type : Large molecule
Upfront Cash : $20.0 million
October 14, 2021
Lead Product(s) : DARPin-conjugated Radioligand Therapies
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $580.0 million
Deal Type : Acquisition
Lead Product(s) : Abicipar Pegol
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Partnership
Molecular Partners to Regain Global Rights to Abicipar
Details : Abicipar is a long-acting anti-VEGF DARPin® molecule which was invented by Molecular Partners and initially licensed to Allergan in 2011.
Brand Name : AGN-150998
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 09, 2021
Lead Product(s) : Abicipar Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : J.P. Morgan
Deal Size : $63.8 million
Deal Type : Public Offering
Details : MP0420 is a clinical-stage candidate that is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ infectious disease program.
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 15, 2021
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : J.P. Morgan
Deal Size : $63.8 million
Deal Type : Public Offering
LOOKING FOR A SUPPLIER?